Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19

Andreas Michael Bucher,Malte M Sieren,Felix G Meinel,Roman Kloeckner,Matthias A Fink,Marwin-Jonathan Sähn,Andreas Wienke,Hans-Jonas Meyer,Tobias Penzkofer,Julia Dietz,Thomas J Vogl,Jan Borggrefe,Alexey Surov,RACOON Study Group,Alexander Gussew,Alexander König,Andreas Bucher,Andreas Mahnken,Arno Bücker,Bernd Hamm,Birte Valentin,Christian Stroszczynski,Christiane Kuhl,Christoph Düber,Christopher Kloth,Daniel Kütting,David Maintz,Elmar Kotter,Evelyn Bohrer,Fabian Bamberg,Felix Güttler,Florian Schwarz,Frank Wacker,Frederik Kostka,Gabriele Krombach,Gerald Antoch,Gerhard Adam,Gudrun Borte,Hans-Ulrich Kauczor,Hinrich Winther,Jens Kleesiek,Jens Ricke,Jens-Peter Kühn,Joachim Lotz,Jörg Barkhausen,Kersten Peldschus,Konstantin Nikolaou,Maciej Pech,Malte Sieren,Marc-André Weber,Marcus Both,Marcus Makowski,Matthias Fink,Matthias Frölich,Matthias May,Meinrad Beer,Michael Forsting,Michael Ingrisch,Michael Uder,Norbert Hosten,Okka Hamer,Olav Jansen,Peter Isfort,Philipp Josef Kuhl,Ralf-Thorsten Hoffmann,Rickmer Braren,Robert Rischen,Saheeb Ahmed,Saif Afat,Simon Pätzholz,Stefan Schönberg,Thomas Kröncke,Thomas Vogl,Thorsten Bley,Thorsten Persigehl,Timm Denecke,Ulf Teichgräber,Ulrike Attenberger,Volkmar Nicolas,Walter Heindel,Walter Wohlgemuth
DOI: https://doi.org/10.1055/a-2293-8132
2024-07-22
Abstract:Purpose: The prevalent coronavirus disease 2019 (COVID-19) pandemic has spread throughout the world and is considered a serious threat to global health. The prognostic role of thoracic lymphadenopathy in COVID-19 is unclear. The aim of the present meta-analysis was to analyze the prognostic role of thoracic lymphadenopathy for the prediction of 30-day mortality in patients with COVID-19. Materials and methods: The MEDLINE library, Cochrane, and SCOPUS databases were screened for associations between CT-defined features and mortality in COVID-19 patients up to June 2021. In total, 21 studies were included in the present analysis. The quality of the included studies was assessed by the Newcastle-Ottawa Scale. The meta-analysis was performed using RevMan 5.3. Heterogeneity was calculated by means of the inconsistency index I2. DerSimonian and Laird random-effect models with inverse variance weights were performed without any further correction. Results: The included studies comprised 4621 patients. The prevalence of thoracic lymphadenopathy varied between 1 % and 73.4 %. The pooled prevalence was 16.7 %, 95 % CI = (15.6 %; 17.8 %). The hospital mortality was higher in patients with thoracic lymphadenopathy (34.7 %) than in patients without (20.0 %). The pooled odds ratio for the influence of thoracic lymphadenopathy on mortality was 2.13 (95 % CI = [1.80-2.52], p < 0.001). Conclusion: The prevalence of thoracic lymphadenopathy in COVID-19 is 16.7 %. The presence of thoracic lymphadenopathy is associated with an approximately twofold increase in the risk for hospital mortality in COVID-19. Key points: · The prevalence of lymphadenopathy in COVID-19 is 16.7 %.. · Patients with lymphadenopathy in COVID-19 have a higher risk of mortality during hospitalization.. · Lymphadenopathy nearly doubles mortality and plays an important prognostic role.. Citation format: · Bucher AM, Sieren M, Meinel F et al. Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19. Fortschr Röntgenstr 2024; DOI: 10.1055/a-2293-8132.
What problem does this paper attempt to address?